Jump to main content Jump to sidebar

blurb.social: Discover the web

Forums

Log in
Sign up

Overview
Submissions
Comments

astrazenecacom1757

Full Year and Q4 2023 results - AstraZeneca

astrazeneca.com

Submitted by astrazenecacom1757 on February 9, 2024 at 7:00 AM in business

No comments

27

AstraZeneca launches healthtech business Evinova - AstraZeneca

astrazeneca.com

Submitted by astrazenecacom1757 on November 21, 2023 at 10:35 AM in business

No comments

40

Update on PACIFIC-2 Phase III trial of Imfinzi concurrently administered with platinum-based chemoradiotherapy in unresectable, Stage III non-small cell lung cancer - AstraZeneca

astrazeneca.com

Submitted by astrazenecacom1757 on November 15, 2023 at 1:35 AM in business

No comments

28

ERROR: The request could not be satisfiedDatopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial - AstraZeneca

astrazeneca.com

Submitted by astrazenecacom1757 on September 22, 2023 at 1:30 AM in business

No comments

1

ERROR: The request could not be satisfiedDatopotamab deruxtecan met dual primary endpoint of progression-free survival in patients with advanced non-small cell lung cancer in TROPION-Lung01 Phase III trial - AstraZeneca

astrazeneca.com

Submitted by astrazenecacom1757 on July 3, 2023 at 1:30 AM in business

No comments

49

astrazenecacom1757

Registered on July 4, 2023

We love you.